Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Diabetes Right
  3. Mounjaro (tirzepatide) injection Right
  4. What is the incidence of nausea in adults with type 2 diabetes taking Mounjaro® (tirzepatide)?
Search Mounjaro (tirzepatide) injection (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Mounjaro ® (tirzepatide) injection

2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the incidence of nausea in adults with type 2 diabetes taking Mounjaro® (tirzepatide)?

Gastrointestinal adverse events, including nausea, were the most frequently reported adverse reactions in clinical trials with tirzepatide. Incidence decreased over time and was comparable to the GLP-1 receptor agonist class.

US_cFAQ_TZP044A_M_NAUSEA
US_cFAQ_TZP044A_M_NAUSEAen-US

See important safety information, including boxed warning, in the attached prescribing information.

Nausea

Mounjaro (tirzepatide) is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) for once-weekly, subcutaneous administration.1

Reported gastrointestinal (GI) adverse events (AEs), including nausea, were the most frequently reported adverse reactions in clinical trials with tirzepatide. The majority of the reported GI AEs occurred during dose escalation and decreased over time.1

In pooled data derived from 2 placebo-controlled trials with a mean treatment duration of 36.6 weeks, nausea was reported in

  • 18% of patients receiving tirzepatide 15 mg
  • 15% of patients receiving tirzepatide 10 mg
  • 12% of patients receiving tirzepatide 5 mg, and
  • 4% of patients receiving placebo.1

Across 5 clinical studies, SURPASS-1, 2, 3, 4, and 5, the percent of patients experiencing nausea ranged between

  • 18% to 24% for tirzepatide 15 mg
  • 13% to 23% for tirzepatide 10 mg, and
  • 12% to 17% for tirzepatide 5 mg.2-6 

The study design for the SURPASS clinical trial program included a 20 week dose escalation phase. The starting dose of tirzepatide was 2.5 mg once weekly for 4 weeks, escalated in 2.5 mg increments every 4 weeks until the assigned dose of 5, 10, or 15 mg was achieved. 2-6

The slow dose escalation scheme used in the SURPASS clinical trial program was associated with a better GI AE profile than the rapid dose escalation scheme used in the phase 2 trial.3

The incidence of nausea with tirzepatide, which refers to the proportion of participants who experienced a new event during a specified time interval, decreased over time during clinical trials and was comparable to the GLP-1 receptor agonist class.1,7

The incidence of nausea over time in SURPASS-2, which compared tirzepatide with semaglutide 1 mg, is shown in Incidence of Nausea Over Time Through 40 Weeks in SURPASS-2.3 

Incidence of Nausea Over Time Through 40 Weeks in SURPASS-23

Figure 1 description: In SURPASS-2, tirzepatide 5 mg, 10 mg, and 15 mg, and semaglutide 1 mg each demonstrated similar rates of nausea during initiation but decreased over time. 

Abbreviations: mITT = modified intention-to-treat; SEMA = semaglutide; TZP = tirzepatide.

Data are percent of participants who reported a new event relative to participants at risk during a time interval; mITT population (safety analysis set). Shaded areas indicate the period of time before reaching the maintenance dose of the study treatments. Incidence refers to the proportion of participants who have a new event during a time interval. 

Use of Antiemetic Medication in SURPASS-1 to -5

The clinical trial protocols for SURPASS-1 to -5 provided information on the management of patients with GI symptoms. Among other options to mitigate GI symptoms and manage patients with intolerable GI AEs, the investigator was asked to

  • advise patients to eat smaller meals and to stop eating when they feel full, and
  • prescribe symptomatic medication (eg, antiemetic medication) per local country availability and individual patient needs.8 

Use of symptomatic medication was captured as concomitant medication in the study record.8

In the SURPASS-1 to -5 trials, the proportion of tirzepatide-treated patients who received antiemetic medications during the course of the trial is shown in (Proportion of Patients Taking 1 or More Antiemetic Medication During the Study Treatment Period in SURPASS-1 to -5).8

Proportion of Patients Taking 1 or More Antiemetic Medication During the Study Treatment Period in SURPASS-1 to -58

Trial

Tirzepatide 5 mg

Tirzepatide 10 mg

Tirzepatide 15 mg

SURPASS-1

10/121 (8.3)

9/121 (7.4)

11/121 (9.1)

SURPASS-2

67/470 (14.3)

71/469 (15.1)

101/470 (21.5)

SURPASS-3

22/358 (6.1)

36/360 (10.0)

52/359 (14.5)

SURPASS-4

33/329 (10.0)

47/328 (14.3)

63/338 (18.6)

SURPASS-5

7/116 (6.0)

13/119 (10.9)

12/120 (10.0)

Abbreviation: mITT = modified intention-to-treat.

Note: Data is n/N (%) from the mITT population (full analysis set), defined as the number of patients who were randomized and received at least 1 dose of study drug per the assigned treatment group.

n = number of patients in the assigned treatment group that reported taking ≥1 antiemetic medication during the study treatment period.

N = number of patients in the assigned treatment group who were randomized and received at least 1 dose of study drug.

Enclosed Prescribing Information

MOUNJARO® (tirzepatide) injection, for subcutaneous use, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.

2Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. https://doi.org/10.1016/S0140-6736%2821%2901324-6

3Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519

4Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583-598. https://doi.org/10.1016/S0140-6736(21)01443-4

5Del Prato S, Kahn SE, Pavo I, et al; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824. https://doi.org/10.1016/S0140-6736(21)02188-7

6Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534-545. https://doi.org/10.1001/jama.2022.0078

7Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251-1261. https://doi.org/10.1007/s00125-022-05715-4

8Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: June 08, 2023

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.44 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly